{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-22-293893","form_type":"8-K","ticker":"MIRM","cik":"0001759425","company_name":"Mirum Pharmaceuticals, Inc.","filed_at":"2022-11-29T23:59:59+00:00","discovered_at":"2026-05-14T18:03:52.008688+00:00","generated_at":"2026-06-21T12:22:13.997729+00:00","sec_items":["8.01"],"event_type":"other_material","sentiment":"negative","materiality_score":0.65,"calibrated_materiality_score":0.65,"confidence":"high","headline":"Mirum discontinues OHANA Phase 2b trial of volixibat in ICP due to enrollment feasibility","bullets":["Discontinued Phase 2b OHANA trial of volixibat for intrahepatic cholestasis of pregnancy (ICP).","Interim analysis showed meaningful reductions in serum bile acids and pruritus in treated patients.","Decision driven by unique enrollment challenges in high-risk pregnancy setting.","Company will prioritize other pipeline programs following the discontinuation."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-22-293893","json":"https://secwatch.observer/filing/0001193125-22-293893.json","markdown":"https://secwatch.observer/filing/0001193125-22-293893.md","text":"https://secwatch.observer/filing/0001193125-22-293893.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1759425/000119312522293893/0001193125-22-293893-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1759425/000119312522293893/d426142d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-21T12:22:13.997729+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}